文献速递中医内科中药与中成药合理使用

不同中药制剂联合EGFR-TKIs治疗非小细胞肺癌的网状Meta分析

Efficacy and Safety of Different Types of Traditional Chinese Medicine Preparations Combined with EGFR-TKIs for Patients with Non-Small Cell Lung Cancer: A Network Meta-analysis.
PubMed 文献 · Chin J Integr Med · 2025-12-15

本研究通过网状Meta分析比较EGFR-TKIs单药与联合中药复方、中药注射剂或中成药治疗NSCLC的疗效与安全性。纳入155项RCT共12441例患者,结果显示联合治疗可提高ORR和DCR、降低PD风险,且中药复方可能减少皮疹发生。

要点

  • EGFR-TKIs联合中药复方、注射剂或中成药较单药提高ORR和DCR并降低PD风险。
  • 中药复方联合EGFR-TKIs可能降低皮疹发生率。
  • 中药注射剂联合方案在提高ORR方面可能优于中药复方联合方案。

核心结论

  • EGFR-TKIs联合中药复方、中药注射剂或中成药较单药可提高ORR和DCR并降低PD风险。
  • 中药复方联合EGFR-TKIs可能降低皮疹发生率。

研究设计与样本

  • 系统检索多个数据库至2025年2月26日的RCT,纳入155项RCT共12441例NSCLC患者。
  • 采用配对比较和贝叶斯网状Meta分析,二分类结局计算OR及95%CI或95%CrI。

主要发现

  • EGFR-TKIs单药较中药复方联合PD风险高(OR 2.43,95%CrI 2.11-2.76)。
  • EGFR-TKIs单药较中药注射剂联合PD风险高(OR 2.98,95%CrI 2.47-3.58)。
  • EGFR-TKIs单药较中成药联合PD风险高(OR 1.94,95%CrI 1.44-2.64)。
  • 中成药联合较中药注射剂联合PD风险低(OR 0.65,95%CrI 0.46-0.94)。
  • 中药复方、中药注射剂和中成药联合的ORR均高于EGFR-TKIs单药(OR分别为0.53、0.43、0.52)。

关键数值与推荐

  • ORR:中药复方联合OR 0.53(95%CrI 0.47-0.59),中药注射剂联合OR 0.43(95%CrI 0.36-0.50),中成药联合OR 0.52(95%CrI 0.40-0.68),均优于单药。
  • DCR:中药复方联合OR 0.39(95%CrI 0.34-0.46),中药注射剂联合OR 0.33(95%CrI 0.26-0.42),中成药联合OR 0.57(95%CrI 0.41-0.77),均优于单药。
  • 皮疹:单药较中药复方联合OR 1.82(95%CrI 1.46-2.30),较中药注射剂联合OR 1.55(95%CrI 1.01-2.41)。
  • 腹泻:单药较中药复方联合OR 2.52(95%CrI 1.99-3.21),较中成药联合OR 2.56(95%CrI 1.43-4.58)。
  • 药物性肝损伤:单药较中药复方联合OR 2.02(95%CrI 1.33-3.13)。

临床怎么用

  • 对EGFR突变晚期NSCLC患者,可考虑EGFR-TKIs联合中药复方、中药注射剂或中成药以改善疗效。
  • 联合中药复方可能有助于减少EGFR-TKIs相关皮疹。
  • 选择联合方案时需综合评估疗效与安全性,并注意不同中药制剂类型的差异。

局限性

  • 需进一步设计良好的RCT比较不同联合策略的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer remains one of the most malignant cancers worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are recommended as first-line treatments for advanced EGFR-mutated NSCLC. Classical Chinese herb formulas have shown potential clinical benefits in NSCLC management. However, few studies have systematically compared the efficacy and safety of EGFR-TKIs monotherapy versus EGFR-TKIs combined with classical Chinese herb formulas. OBJECTIVE: To evaluate the efficacy and safety of EGFR-TKIs monotherapy versus EGFR-TKIs combined with classical Chinese herb formulas in the treatment of NSCLC. METHODS: A systematic search was conducted to identify randomized controlled trials (RCTs) in which patients with NSCLC were randomly assigned to receive either EGFR-TKIs monotherapy or EGFR-TKIs combined with classical Chinese herbal formulas. The combined regimens include EGFR-TKIs plus Chinese herbal compounds (CHCT), EGFR-TKIs plus Chinese traditional medicine injections (CTMIT), and EGFR-TKIs plus Chinese patent medicines (CPMT). Electronic databases search included PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Wanfang Data, VIP Database, the International Clinical Trial Registry Platform, and the Chinese Clinical Trial Registry, from inception updated to February 26, 2025. Given that all outcomes were binary, odds ratios (ORs) along with 95% confidence intervals (CIs) were computed. Pairwise comparisons and Bayesian network meta-analyses were used for the same outcome assessment, including progressive disease (PD), disease control rate (DCR), objective response rate (ORR), rash, diarrhea, and drug-induced liver injury (DILI) with the former reporting ORs and 95% CIs while the latter ORs and 95% credible intervals (CrIs). RESUTS: A total of 155 RCTs involving 12,441 patients with NSCLC were included. For efficacy outcomes, EGFR-TKIs monotherapy was associated with a higher risk of PD compared with CHCT (OR: 2.43, 95% CrI: 2.11-2.76), CTMIT (OR: 2.98, 95% CrI: 2.47-3.58), and CPMT (OR: 1.94, 95% CrI: 1.44-2.64) combination therapies, while CPMT was associated with a lower risk of PD than CTMIT (OR: 0.65, 95% CrI: 0.46-0.94). In terms of ORR, CHCT (OR: 0.53, 95% CrI: 0.47-0.59), CTMIT (OR: 0.43, 95% CrI: 0.36-0.50), and CPMT (OR: 0.52, 95% CrI: 0.40-0.68) combination therapies all demonstrated significantly higher ORR than EGFR-TKIs monotherapy, with CTMIT also showing a higher ORR compared with CHCT (OR: 0.81, 95% CrI: 0.67-0.99). For DCR, combination therapy with CHCT (OR: 0.39, 95% CrI: 0.34-0.46), CTMIT (OR: 0.33, 95% CrI: 0.26-0.42), and CPMT (OR: 0.57, 95% CrI: 0.41-0.77) combination therapies were superior to EGFR-TKIs monotherapy, and both CHCT (OR: 1.44, 95% CrI: 1.01-2.05) and CTMIT (OR: 1.70, 95% CrI: 1.16-2.50) showed better DCR than CPMT. For safety outcomes, EGFR-TKIs monotherapy was associated with a higher incidence of rash compared with CHCT (OR: 1.82, 95% CrI: 1.46-2.30) and CTMIT (OR: 1.55, 95% CrI: 1.01-2.41) combination therapies, a higher incidence of diarrhea compared with CHCT (OR: 2.52, 95% CrI: 1.99-3.21) and CPMT (OR: 2.56, 95% CrI: 1.43-4.58), and a higher incidence of DILI compared with CHCT (OR: 2.02, 95% CrI: 1.33-3.13). CONCLUSIONS: This study provides evidence to support the potential value of combining Chinese herbal formulas with EGFR-TKIs in the treatment of NSCLC, aligning with current clinical guidelines. The findings indicate that EGFR-TKIs combined with Chinese herbal formulas (CHCT, CTMIT, CPMT) are associated with higher ORR and DCR, and a lower risk of PD, compared with EGFR-TKIs monotherapy. Additionally, CHCT may reduce the incidence of rash in EGFR-TKIs treated patients. Further well-designed RCTs are warranted to compare the efficacy and safety of different combined therapeutic strategies in NSCLC patients. (Registration No. CRD42024521654).

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Zhang CC, Zhang JY, Liu Y, et al. Efficacy and Safety of Different Types of Traditional Chinese Medicine Preparations Combined with EGFR-TKIs for Patients with Non-Small Cell Lung Cancer: A Network Meta-analysis. Chin J Integr Med. 2025. PMID: 41396392. doi:10.1007/s11655-025-4150-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。